Absci Corp. (ABSI)
NASDAQ:ABSI
Want to see ABSI full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.24Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed clear progress on the lead program (ABS-201) with favorable early safety/PK signals, supportive PK modeling for an infrequent dosing profile, a defined clinical timeline (interim 13-week readout in H2 2026 and full 26-week POC in early 2027), and a substantial addressable market supported by consumer and KOL research. The company expanded its prolactin-focused pipeline (ABS-202), sharpened strategic focus by de‑emphasizing oncology, and reported a cash runway into H1 2028. Offsetting these positives are a very small quarter revenue base ($200k), a cash decline of ~12.9% QoQ to $125.7M, increased R&D spend (+17.7% YoY), and remaining clinical and regulatory risks (directional 13-week readout, placebo risk in endometriosis). Overall, the call emphasized promising clinical and commercial potential but also highlighted near-term execution and financing sensitivities.Company Guidance
ABS-201 HEADLINE Trial Progressing On Track
Phase I/IIa HEADLINE trial tracking to plan: all 4 single ascending dose (SAD) cohorts dosed and first multiple ascending dose (MAD) cohort initiated. Emerging safety and tolerability data described as favorable, with blinded preliminary safety, tolerability and PK data expected next month. Interim 13-week directional hair regrowth readout planned for H2 2026 and full 26-week proof-of-concept (POC) readout expected early 2027.
PK Modeling Supports Infrequent Dosing
Preliminary PK modeling from SAD cohorts supports a targeted dosing interval of 2–3 injections over a 6-month period (management noted the ability to dose at least every ~8 weeks subcutaneously). Company to provide refined PK/dosing estimates with upcoming data release.
Pipeline Expansion with ABS-202 (Anti‑Prolactin Receptor)
Announced a new anti-prolactin receptor antibody program, ABS-202, targeting an inflammatory & immunology (I&I) indication. Expands the company's prolactin-focused pipeline beyond ABS-201 (AGA/endometriosis) and demonstrates platform leverage.
Large Market Opportunity Supported by Market Research
Company estimates potential U.S. total available market (TAM) exceeding $25 billion for ABS-201 under the target product profile (TPP). Management also cited potential peak sales for ABS-201 in endometriosis in excess of $4 billion. Consumer survey responses: 87% of men and 69% of women said they would seek ABS-201 today if available; among patients already on standard of care these rose to 92% (men) and 89% (women).
Strategic Focus and Potential Cost/Time Efficiencies
Management emphasized a focused strategy on developing differentiated therapeutic assets (prolactin biology), potential to leverage SAD/MAD data to support Phase II initiation in endometriosis, and the possibility of an expedited pathway (potential to advance directly to registrational trials). Aggressive rollout of agentic AI workflows reported to be creating meaningful efficiency and capability gains.
Financial Position and runway
Cash, cash equivalents and marketable securities of $125.7 million as of March 31, 2026. Management believes cash runway is sufficient to fund operating plans into the first half of 2028, supporting execution of upcoming clinical catalysts (interim and full POC readouts and potential Phase II initiation in endometriosis).
ABSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $5.75 | $5.90 | +2.61% |
Mar 24, 2026 | $3.01 | $2.92 | -2.99% |
Nov 12, 2025 | $3.40 | $2.64 | -22.35% |
Aug 12, 2025 | $2.97 | $3.12 | +5.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Absci Corp. (ABSI) report earnings?
Absci Corp. (ABSI) is schdueled to report earning on Aug 18, 2026, Before Open (Confirmed).
What is Absci Corp. (ABSI) earnings time?
Absci Corp. (ABSI) earnings time is at Aug 18, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABSI EPS forecast?
ABSI EPS forecast for the fiscal quarter 2026 (Q2) is -0.2.